JNJ · Earnings call · 2026Q3T · Full report
Vision Product Adoption
JOHNSON & JOHNSON · 2026-10-13 · Importance 25 · Surprise 32 · In source text
Vision grew 5.1%, supported by premium innovation, commercial execution and global reach. Surgical vision grew 7.1% on new products and robust demand for premium intraocular lenses, while contact lenses grew 4.3% on the ACUVUE OASYS 1-Day family. TECNIS PureSee and TECNIS Odyssey exceeded one million implants worldwide, indicating continued surgeon adoption of premium personalized-vision products. Johnson & Johnson also received European CE marking for reusable ACUVUE OASYS MAX two-week lenses, expanding its European portfolio.
Key facts
- ACUVUE OASYS MAX two-week reusable lenses received CE marking in Europe.
- TECNIS PureSee and TECNIS Odyssey surpassed one million implants worldwide during the quarter.
- Contact lenses and other products grew 4.3% in the quarter, driven by ACUVUE OASYS 1-Day family performance.
- Surgical vision delivered growth of 7.1% in the quarter.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | ACUVUE OASYS MAX two-week reusable lenses received CE marking in Europe. |